A study of 783 patients treated with CAR T cell therapy found no evidence that the therapy itself caused secondary cancers.

Trenchant partnered with Autolomous, integrating its digital solution into its CGT manufacturing platform, for faster production and lower costs.

A major limitation of this type of CAR T cell therapy, called autologous therapy, is that the cells are taken from the ...

Researchers at Cellectis leveraged gene editing to create a CAR T cell that acts in an IF/THEN system. Traditional methods to develop CAR T cells that use the patient’s cells introduce challenges ...

In a new study, scientists have found that CAR-T cells are able to donate this synthetic protein to normal T cells, essentially arming other cells in the immune system with advanced technology to ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which uses "switchable" cells that aim to eliminate the life-threatening side-effects ...

CARsgen’s allogeneic CD38 CAR-T therapy administers first dose in an investigator-initiated trial: Shanghai, China Tuesday, January 21, 2025, 18:00 Hrs [IST] CARsgen Therapeutic ...